Panos Christakis (Yale University School of Medicine), 2011-06: The Yale account of the first human nitrogen mustard treatment: patient 'JD', lymphosarcoma refractory to radiation, first dose 27 August 1942 at 0.1 mg/kg, ten daily intravenous injections, tumour regression then marrow failure, death 1 December 1942 (day 96) with 'extreme aplasia of the bone marrow'. It documents War Department censorship of the term in the chart, OSRD funding of the Yale contract, and the distinction the authors draw between therapeutic use in JD and experimental use on military volunteers.
nowhere in JD's record do the words "nitrogen mustard" appear; rather, the substance was referred to as "a lymphocidal" or "substance X."
Section: JD's History
Panos Christakis (Yale University School of Medicine), 2011-06: The Yale account of the first human nitrogen mustard treatment: patient 'JD', lymphosarcoma refractory to radiation, first dose 27 August 1942 at 0.1 mg/kg, ten daily intravenous injections, tumour regression then marrow failure, death 1 December 1942 (day 96) with 'extreme aplasia of the bone marrow'. It documents War Department censorship of the term in the chart, OSRD funding of the Yale contract, and the distinction the authors draw between therapeutic use in JD and experimental use on military volunteers. Funder: OSRD (Office of Scientific Research and Development, War Department) contract to Yale School of Medicine, per the article. Conflicts: not applicable/not declared. Maker: nitrogen mustard supplied under the OSRD/Chemical Warfare Service programme; no commercial manufacturer named. Comparator: none – single named patient, no control, no consent form, treatment framed as last-resort therapy. Verbatim on consent (Section JD's History): 'JD maintained the will to survive and agreed to undergo experimental chemotherapy.' On secrecy: 'As a result of censoring by the War Department…' and 'a distinction must be made between the therapeutic use of nitrogen mustard on JD and its experimental use on military volunteers.' Secondary/peer-reviewed institutional history, not the 1946 JAMA paper.
